Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ: PCRX )

22.36 +0.30 (+1.36%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 930,322
Open 22.05
Bid (Size) 20.80 (1)
Ask (Size) 22.80 (1)
Prev. Close 22.06
Today's Range 21.50 - 22.67
52wk Range 11.16 - 34.01
Shares Outstanding 44,454,792
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PCRX Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Pacira BioSciences, Inc.
From Robbins LLP
Via GlobeNewswire
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire

Performance

YTD
+21.99%
+21.99%
1 Month
+16.52%
+16.52%
3 Month
+27.84%
+27.84%
6 Month
+15.44%
+15.44%
1 Year
-29.53%
-29.53%

More News

Read More
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
6 Analysts Assess Pacira BioSciences: What You Need To Know
Via Benzinga
Decoding 6 Analyst Evaluations For Pacira BioSciences
Via Benzinga
Evaluating Pacira BioSciences: Insights From 8 Financial Analysts
Via Benzinga
PACIRA BIOSCIENCES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
From Kahn Swick & Foti, LLC
Via Business Wire
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
From Faruqi & Faruqi LLP
Via GlobeNewswire
Rosen Law Firm Urges Pacira BioSciences, Inc. (NASDAQ: PCRX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
Via Benzinga
Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain
Via Benzinga
Exposures Product Safety
Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Lost Money on Pacira BioSciences, Inc.(PCRX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
Via ACCESSWIRE
Shareholder Rights Advocates at Levi & Korsinsky Investigate Pacira BioSciences, Inc. (PCRX) Regarding Possible Securities Fraud Violations
Via ACCESSWIRE
Pacira BioSciences, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Pacira BioSciences, Inc. (PCRX)
Via ACCESSWIRE
Investors seeking growth at a reasonable cost should explore NASDAQ:PCRX.
Via Chartmill
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Pacira BioSciences
Via GlobeNewswire
Pacira Awarded New U.S. Patent Covering EXPAREL Composition
From Pacira BioSciences
Via GlobeNewswire
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Third Quarter 2024 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.